Pharmacological Management of Psoriasis
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Department of Pharmacology and Pharmacotherapy | hu_HU |
dc.contributor.author | Shah, Aleena Nauman | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Szentmiklósi, József András | |
dc.contributor.opponentdept | Kenézy Kórház, Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2022-01-18T09:42:05Z | |
dc.date.available | 2022-01-18T09:42:05Z | |
dc.date.created | 2021-10-08 | |
dc.description.abstract | This literature review explores the currently available and potential pharmacotherapies targeting psoriasis, as well as the underlying pathomechanism and associated risk factors. The treatment options discussed are the biologics, phototherapy, vitamin D analogs, and topical agents, along with their side effects and performance in clinical trials. | hu_HU |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 36 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/327930 | |
dc.language.iso | en | hu_HU |
dc.subject | Psoriasis | hu_HU |
dc.subject | Management | hu_HU |
dc.subject | Pharmacological | hu_HU |
dc.subject | Psoriatic | hu_HU |
dc.subject | Dermatology | hu_HU |
dc.subject | Biologics | hu_HU |
dc.subject | Secukinumab | hu_HU |
dc.subject | Ixekizumab | hu_HU |
dc.subject | Brodalumab | hu_HU |
dc.subject | Ustekinumab | hu_HU |
dc.subject | Guselkumab | hu_HU |
dc.subject | Fingolimod | hu_HU |
dc.subject | PUVA | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Pharmacological Management of Psoriasis | hu_HU |